<DOC>
	<DOCNO>NCT01952756</DOCNO>
	<brief_summary>1 . The number function circulate endothelial progenitor cell ( EPCs ) inversely associate coronary risk factor atherosclerotic disease PAOD . 2 . This double-blind , randomize , placebo-controlled trial evaluate effect cilostazol human early EPCs angiogenesis well potential mechanism action patient mild-to-moderate PAOD .</brief_summary>
	<brief_title>Effect Cilostazol Endothelial Progenitor Cells Collateral Formation Peripheral Occlusive Artery Disease ( PAOD )</brief_title>
	<detailed_description>1. titration drug 1. run-in period : eligible subject screen baseline blood sample obtain 2. study period : 12 week - 24 subject cilostazol 20 subject dummy placebo - On first day end study period , follow-up data obtain procedure 3. blood sample measurement serum biomarkers - obtain peripheral vein study subject run-in period end treatment period study - sent isolation , cell culture , assay human EPCs - also store enzyme-linked immunosorbent assay ( Stromal cell derive factor-alfa1 , adiponectin , soluble thrombomodulin , vascular endothelial growth factor ) 2. assay human EPCs 1. colony formation EPCs 2. quantification EPCs apoptotic endothelial cell 3. chemotactic motility , proliferation/viability apoptosis assay 3. collateral vessel formation distal run-off assess dual-energy multi-slice compute tomography angiography 4. echocardiographic examination evaluate leave ventricular function</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>anklebrachial index ( ABI ) less 0.9 one leg obvious symptom intermittent claudication obvious symptom intermittent claudication severe PAD ( Fontaine grade &gt; 3 ) critical limb ischemia least one leg severe liver dysfunction ( transaminases &gt; 10 time upper normal limit , history liver cirrhosis , hepatoma ) &gt; stage 4 chronic kidney disease ( endstage renal disease chronic dialysis exclude ) leave ventricular ejection fraction &lt; 50 % echocardiography document active malignancy chronic inflammatory disease plan coronary intervention endovascular therapy bypass surgery within 3 month know drug allergy history cilostazol current use cilostazol cAMPelevator premenopausal woman</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>cilostazol</keyword>
	<keyword>endothelial progenitor cell</keyword>
	<keyword>vasculogenesis</keyword>
	<keyword>angiogenesis</keyword>
	<keyword>peripheral arterial disease</keyword>
	<keyword>biomarkers</keyword>
</DOC>